SCHEMBL16201369

SCHEMBL16201369

CCCN(C)Cc1n[nH]cc1-c1ccc(OC2CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.40
BTK Q06187 1/20 0.34
KCNH2 Q12809 2/20 0.33
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
KHK P50053 1/20 0.33
PRMT3 O60678 1/20 0.32
CARM1 Q86X55 1/20 0.32
PRMT6 Q96LA8 1/20 0.32
PRMT1 Q99873 1/20 0.32
PRMT8 Q9NR22 1/20 0.32
CHEK2 O96017 1/20 0.32
TGFBR1 P36897 2/20 0.32
ACVR1 Q04771 2/20 0.32
ACVR1B P36896 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
PTPN1 P18031 1/20 0.31
MAP4K1 Q92918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201209 0.89 CARM1 (0.43) HRH3BTKKCNH2PRMT5WDR77
SCHEMBL16201372 0.83 SPHK1 (0.33) MAP4K1
SCHEMBL16201365 0.81 HRH3 (0.42) HRH3PRMT3CARM1PRMT6PRMT1
SCHEMBL16201444 0.81 LTA4H (0.41)
SCHEMBL16201380 0.80 CRHR1 (0.36) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201340 0.80 TDO2 (0.33) ALDH1A1
SCHEMBL16201364 0.80 PRMT6 (0.44) PRMT6PRMT1
SCHEMBL16201384 0.80 PRMT3 (0.40) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201392 0.78 IL2 (0.38) HRH3KCNH2ALDH1A1MAP4K1
SCHEMBL16201371 0.78 NPSR1 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 HRH3 1068/4885BTK 2039/4885KCNH2 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.